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JPGN  Volume 65, NABSTRACTWhat Is Known
 Perianal Crohn disease occurs in approximately 30%
of patients over the course of disease.
 Adult studies showed that perianal disease is associ-
ated with luminal complications.
 Data on the phenotypic features and natural history
of perianal Crohn disease are scarce.
What Is New
 Patients with perianal Crohn disease have a greater
inflammatory burden.
 Nevertheless, we did not observe higher rates of
luminal damage associated with this phenotype.
 Isolated noninflamed skin tags and/or fissures are not
associated with severe phenotype, and thus may not
require a radiologic evaluation or treatment escalation.Objectives: Data on the outcomes of children with perianal Crohn disease
(pCD) are limited, although its presence is often used for justifying early use
of biologics. We aimed to assess whether pCD in children is associated with
more severe outcomes as found in adults.
Methods: Data were extracted from the ImageKids database, a prospective,
multicenter, longitudinal cohort study. The study enrolled 246 children at
disease onset or thereafter. All patients underwent comprehensive clinical,
endoscopic, and radiologic evaluation at enrollment; 98 children had repeat
evaluation at 18 months.
Results: Of the 234 included patients (mean age 14.2 2.4 years; 131 [56%]
boys), 57 (24%) had perianal findings, whereas only 21 (9%) had fistulizing
perianal disease. Children with pCD had reduced weight and height z scores
compared with non-pCD patients (0.9 vs 0.35, P¼ 0.03 and 0.68 vs
0.23, respectively; P¼ 0.04), higher weighted pediatric CD activity index
(32 [interquartile range 16–50] vs 20 [8–37]; P¼ 0.004), lower serum
albumin (3.6 0.7 vs 4.5 0.8, P¼ 0.016), and higher magnetic resonance
enterography global inflammatory score (P¼ 0.04). Children with pCD had
more rectal (57% vs 38%, P¼ 0.04), and jejunal involvement (31% vs 11%
P¼ 0.003) and a higher prevalence of granulomas (64% vs 23%, P¼ 0.0001).
Magnetic resonance enterography–based damage scores did not differ
between groups. Patients with skin tags/fissures only, had similar clinical,
endoscopic, and radiologic characteristics as patients with no perianal findings.
Conclusions: Pediatric patients with pCD with fistulizing disease have distinct
phenotypic features and a predisposition to a greater inflammatory burden.
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Assa et al JPGN  Volume 65, Number 3, September 2017intensified medical therapy (2,3). Perianal involvement, including
inflamed skin tags, fistulae, and abscesses is a common, often
debilitating manifestation of CD occurring in approximately 30%
of patients over the course of disease (4,5). Studies in adult patients
with CD have shown that perianal disease is associated with a more
rapid progression from inflammatory to stricturing or penetrating
phenotype, which mandates intensified treatment strategy at disease
onset, often with biologics (6–9). Similar data in children are scarce
although younger adult patients were found to be at the greatest risk
for pCD (6). A recent report indicated that children with CD who
develop perianal fistulae are more likely to require diverting ileost-
omy or colectomy compared with those who do not present with
perianal disease (10). Despite the limited pediatric data and mainly
extrapolating from adult literature, European Crohn’s and Colitis
Organisation/European Society for Paediatric Gastroenterology
Hepatology and Nutrition guidelines for managing pCD state that
the presence of severe perianal disease is a predictive factor for poor
outcome, justifying more aggressive treatment (11).
We therefore aimed to assess whether a perianal phenotype is
associated with more severe outcomes in pediatric CD, and to explore
clinical, laboratory, endoscopic, and radiologic factors associated
with this phenotype on the prospective ImageKids database.
MATERIALS AND METHODS
Setting and Design
Data were extracted from the ImageKids database, which is a
longitudinal, prospective, multicenter cohort study aimed to
develop and evaluate pediatric magnetic resonance enterography
(MRE)-based indices—one of inflammation and one of intestinal
damage. In this ancillary study, we stratified the patients according
to those with and those without perianal disease at enrollment.
Perianal disease was defined as any perianal finding including skin
tags, fissures, fistulae, or abscess either by physical examination or
by pelvic magnetic resonance imaging (pMRI). Fistulizing perianal
disease was defined as a fistula and/or abscess diagnosed by pMRI.
Patients
The ImageKids study enrolled 246 children from 5 to 18
years of age with established diagnosis of CD by the presence of
accepted clinical, radiologic, endoscopic, and histologic criteria
(11). Children were included at any phase of the disease (at
diagnosis and thereafter) according to predefined stratification:
20% within 3 months of diagnosis, 20% between 3 months and
2 years, 20% between 2.01 to 3 years and 40% more than 3 years
from diagnosis. Patients unable to tolerate MRE were excluded. The
first 120 enrolled children were followed for 18 months when MRE
and clinical evaluation were repeated. The present study uses both
the baseline visit and a subgroup of patients who completed the 18
months’ follow-up visit.
At enrollment, all patients underwent ileocolonoscopy, eso-
phagogastroduodenoscopy, and MRE as part of clinical care. pMRI
was performed in all patients unless the perianal area was com-
pletely normal on physical examination and history taking (ie, no
current or previous fissures, skin tags, fistulae, or perianal abscess).
Description of Variables
Explicit demographic, clinical, laboratory, therapeutic, anthro-
pometric, endoscopic, and radiologic data were recorded at enroll-
ment. Data were entered to a Web-based electronic case report file.
Because of different reference values at different centers, C-reactive
protein was analyzed as a categorical variable (normal/abnormal) Copyright © ESPGHAN and NA
294rather than an absolute number. Disease activity was assessed using
the weighted Pediatric CD Activity Index (wPCDAI) and Physician
Global Assessment (PGA) using both categorical analysis (0–3; 0:
quiescent, 1: mild, 2: moderate, 3: severe) and a 100 mm visual analog
scale (in which 0 mm means quiescent disease and 100 mm severe).
Disease phenotype at diagnosis was categorized according to the
Paris classification (12). Height, weight, and body mass index were
converted to age- and sex-adjusted standard deviation scores
(z scores), using the World Health Organization (Anthro and Anthro
plus software for personal computers, version 2, 2007: Software for
assessing growth and development of the world’s children. Geneva:
WHO, 2007 [http://www.who.int/childgrowth/software/en/]). Thera-
pies and surgical interventions from the time of diagnosis to
enrollment were retrieved from medical charts.
MRE and pMRI were assessed by 2 experienced radiologists
who also provided global assessments on the MRE examinations for
both inflammation and damage separately on a 100 mm visual analog
scale (in which 0 mm means no inflammation/damage and 100 mm
severe). Degree of mucosal inflammation and stenosis was recorded
on ileocolonoscopy and esophagogastroduodenoscopy prospectively,
using 2 scoring systems; a global assessment of none, mild, moderate,
and severe, at each endoscopic segment (terminal ileum, ascending
colon, transverse colon, descending colon, rectosigmoid, esophagus,
stomach, and duodenum) and by using the simple endoscopic score
for CD, at each intestinal segment (both in the ileocolon and in the
upper gastrointestinal [UGI] tract (13)).
Data Analyses
Data are reported as proportions (%), means standard devi-
ations, or medians (interquartile range), as appropriate. Continuous
data were compared using Student t test, or the Wilcoxon rank sum
test, as appropriate, for the distribution normality. Categorical vari-
ables were compared using chi-square or Fisher exact, as appropriate,
and were reported as frequency and percentage. Multivariate logistic
regression model was then sought for analyzing the association
between perianal phenotype and selected variables by relevance,
including those found by a univariate analysis with significance of
<0.1. The first block in each regression included age, sex, and pCD.
The second block included potential confounders, which were
selected for inclusion in the regression using the forward method.
For the longitudinal analysis Wilcoxon and McNemar tests
were used to compare parameters between enrollment and end of
follow-up. Generalized estimating equations and linear mixed
model were used to assess interactions for the 3 groups (no perianal
findings, skin tags/fissures only, and perianal fistulizing disease)
between the 2 time points while controlling for age, sex, and time
for diagnosis. P< 0.05 was considered as statistically significant
unless stated otherwise. SPSS version 23 (IBM Corp, Armonk, NY)
was used for all statistical analyses. The study protocol was
approved by each participating site local institutional review board.
RESULTS
Of the 246 enrolled children, 12 had missing perianal data
and thus 234 were included in the present study (Table 1). Fifty-six
patients were enrolled at diagnosis, 50 patients were between 3
months to 2 years after diagnosis and 128 patients were enrolled
with longer disease duration.
Fifty-seven patients (24%) had perianal involvement on
physical examination: 40 of 234 (17%) with skin tags or fissures,
whereas 8 of 40 (20%) were also inflamed. All 57 patients
underwent pMRI. Three of the 8 patients with inflamed skin
tags (37%) had fistulae documented in pMRI compared with only
one of 32 of 40 (3%) with noninflamed skin tags or fissuresSPGHAN. All rights reserved.
www.jpgn.org
TABLE 1. Characteristics of Patients With or Without Perianal Findings (n¼234)
Nonperianal (n¼ 177) Perianal (n¼ 57) Significance (P)
Female, n (%) 78 (44%) 25 (44%) 0.9
Age at diagnosis (y), mean (SD) 11.5 3.3 11.9 2.5 0.1
Age at enrollment (y), mean (SD) 14.2 2.6 14.1 2.1 0.8
Disease duration (y), mean (SD) 2.4 (0.6–2.5) 2 (0.5–3.5) 0.1
Anthropometric measurements, median (IQR)
Weight z score 0.35 (1.3–0.5) 0.9 (1.9–0.2) 0.03
Height z score 0.23 (1.1–0.6) 0.68 (1.4–0.2) 0.04
BMI z score 0.35 (1.3–0.4) 0.77 (1.4–0.2) 0.17
Disease location, n (%)
Ileal (L1) 70 (40%) 14 (25%) 0.08
Colonic (L2) 33 (18%) 10 (18%)
Ileocolonic (L3) 74 (42%) 33 (57%)
Upper GI (L4) 70/157 (45%) 28/52 (56%) 0.1
Disease behavior, n (%)
Inflammatory (B1) 122 (69%) 39 (68%) 0.6
Stricturing (B2) 49 (28%) 14 (25%)
Penetrating (B3) 6 (3%) 4 (7%)
Family history of IBD (first-degree relative), n (%) 32 (18%) 13 (23%) 0.2
Granuloma in histology, n (%) 39/167 (23%) 35/55 (64%) 0.0001
ESR, mean (SD) 21 17 30 19 0.04
Platelets, mean (SD) 353 122 386 133 0.06
Albumin, (g/dL), mean (SD) 4.5 0.8 3.6 0.7 0.016
Hemoglobin (g/dL), mean (SD) 12.7 1.5 11.8 (1.3) 0.15
Abnormal CRP, n (%) 77/165 (47%) 35/55 (60%) 0.15
PGA disease activity (moderate-severe),n (%) 64 (36%) 34 (60%) 0.02
Cecal inflammation, n (%) 55/116 (47%) 27/36 (75%) 0.02
Rectal inflammation, n (%) 67/176 (38%) 32/56 (57%) 0.04
Jejunal inflammation, n (%) 18/162 (11%) 17/54 (31%) 0.003
Surgical resection, n (%) 9 (5%) 4 (7%) 0.7
Time to surgery (y), median (IQR) 2.8 (1.3–4.4) 4.1 (1.8–5.8) 0.1
Treatment history, n (%)
Corticosteroids at enrollment 9/38 (24%) 9/17 (53%) 0.033
Anti-TNFa at enrollment 73/130 (56%) 28/37 (76%) 0.032
Immunomodulators 115/135 (85%) 31/40 (80%) 0.39
Anti-TNFa exposure 70/136 (51%) 27/40 (69%) 0.049
BMI¼ body mass index; CRP¼C-reactive protein; ESR¼ erythrocyte sedimentation rate; GI¼ gastrointestinal; IQR¼ interquartile range; PA¼ perianal;
PGA ¼ Physician Global Assessment; SD ¼ standard deviation; TNFa ¼ tumor necrosis factor a.
Italics represents P < 0.05.
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anal disease confirmed by pMRI (9%) and 36 patients (15%)
with skin tags/fissures (16 patients with skin tags only, 17
patients with skin tags and fissures, and 3 patients with fissures
only) without an underlying fistula. Of patients with fistulizing
perianal disease 10 patients had >1 fistula and 8 patients had
perianal abscess during the study period.
Cross-sectional Analysis
In general, the presence of pCD was positively associated
with most constructs of disease activity measured in the present
study. Children with perianal findings had higher wPCDAI score,
PGA of inflammatory activity, and global MRE inflammatory score
(Fig. 1) compared with those without perianal involvement. Serum
albumin and erythrocyte sedimentation rate similarly differed
between the groups (Table 1). Children with pCD had reduced
median weight z scores (0.9 [interquartile range -1.9–0.2] vs
0.35 [1.3–0.5], P¼ 0.03) and height z scores (0.68 [1.4–0.2]
vs0.23 [1.1–0.6], P¼ 0.04] compared with non-pCD patients.
Finally, pCD was associated with endoscopic disease severity of Copyright © ESPGHAN and NA
www.jpgn.orgthe UGI tract as measured by the UGI-simple endoscopic score for
CD score, but not with ileocolonoscopy (Fig. 2).
Involvement of perianal disease was associated with the need
for more aggressive treatment. More patients with perianal disease
received corticosteroid treatment at enrollment (recorded in all
patients regardless of disease duration at enrollment) and were
exposed more often to antitumor necrosis factor a (TNFa)
therapies (Table 1).
Those with pCD had different disease location with more
jejunal (17/54 [31%] vs 18/162 [11%], P¼ 0.003) and rectal (32/56
[57%] vs 67/176 [38%], P¼ 0.04) involvement. Perianal disease
was also associated with granulomatous disease (35/55 [64%] vs 39/
167 [23%], P¼ 0.001).
At enrollment, there was no difference between pCD and
non-pCD patients in either the proportions of stricturing disease
(15 [27%] vs 50 [28%], P¼ 0.9), or penetrating disease (5 [8%] vs
9 [5%], P¼ 0.2) defined clinically or radiologically, respectively.
Similarly, median PGA total tissue damage score (19 [5–32] vs 12
[4–25], P¼ 0.6) and MRE global damage scores (5 [1–20] vs 11
[2–31], P¼ 0.7) did not differ between pCD and non-pCD patients,

























FIGURE 1. Clinical and radiological indices of patients with and without perianal disease. Analysis of 234 patients (177 with no perianal findings and
77 with perianal findings) shows that median wPCDAI, PGA inflammatory activity, and MRE total inflammatory scores significantly differ between
groups (median: horizontal line, interquartile range [IQR]: box, range: vertical line, white boxes: non perianal, gray boxes: perianal). MRE¼magnetic
resonance enterography; pCD ¼ perianal Crohn disease; PGA ¼ Physician Global Assessment; wPCDAI ¼ weighted Pediatric CD Activity Index.
Assa et al JPGN  Volume 65, Number 3, September 2017resection by the end of the follow-up period with no significant
difference between the groups either in cumulative surgical rate
(15 [8.5%] vs 7, [12%]; P¼ 0.5) or in time to resection.
A subgroup analysis of 21 children with confirmed perianal
fistulae on pMRI showed similar significant differences most
aforementioned outcomes (presence of granulomas, PGA of inflam-
matory activity, wPCDAI score, rectal and jejunal inflammation,
global MRE inflammatory score, and need for anti-TNFa) and lost
significance regarding laboratory and anthropometric measures. In
contrast, a subgroup analysis of 36 children who had skin tags or




















FIGURE 2. Endoscopic SES-CD of patients with and without perianal disea
perianal findings) shows that only upper GI SES-CD differs between groups,
interquartile range [IQR]: box, range: vertical line, white boxes: nonperian
disease; SES-CD ¼ simple endoscopic score for Crohn disease.
296any perianal findings demonstrated no significant difference in any
of the outcomes (Table 2), suggesting that fistulizing perianal
disease contributed most to the differences in the outcomes.
Longitudinal Analysis
Ninety-eight children had their 18-month follow-up visit
completed by the time of the data lock for the present study (56 with
no perianal findings, 23 with skin tags/fissures only, and 19 with
fistulizing perianal disease). Among those without perianal findings









se. Analysis of 234 patients (177 with no perianal findings and 77 with
whereas ileal, colonic, and ileocolonic do not. (median: horizontal line,
al, gray boxes: perianal). GI ¼ gastrointestinal; pCD ¼ perianal Crohn
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enrollment developed perianal fistula during follow-up. All patients
with perianal fistulizing disease but 1 (18 patients, 95%) were
treated with anti-TNFa. There was no difference in the proportion
of patients treated with anti-TNFa between the 2 other groups (34
[61%] patients with no findings compared with 12 [52%] patients
with skin tags, P¼ 0.6). There was no difference in corticosteroids
or immunomodulators’ exposure between groups. Linear mixed
models did not demonstrate significant differences between the 3
groups when analyzing the change in clinical variables, anthropo-
metric measures, and radiologic scores (both inflammation and
damage) between time 0 and 18 months.
Analysis of outcomes at 18 months demonstrated that both
inflammatory PGA and global inflammatory MRE score improved
significantly for the whole cohort (40 [18–63] to 10 [2–22],
P< 0.001]; 51 [20–66] to 28 [14–49], P¼ 0.002) with no signifi-
cant change in damage scores. The presence of perianal disease as
classified in the aforementioned 3 groups did not alter the 18
months’ measures including anthropometric measures, inflamma-
tory global assessments, and damage scores at the end of follow-up.
DISCUSSION
In the present study, using the prospectively accrued data
from the ImageKids cohort, we evaluated phenotypic and clinical
features of pediatric perianal disease. As in adults, pediatric pCD
was associated with worse clinical, laboratory, and anthropometric
measures and with a higher burden of inflammatory activity. These
patients had lower weight and height z scores, lower serum albumin,
higher erythrocyte sedimentation rate, and increased wPCDAI. The
increased rate of active disease was also confirmed radiologically
using MRE inflammatory scores. Furthermore, we observed a
striking difference in jejunal involvement reflecting a higher
inflammatory burden in pCD. Jejunal disease was previously
demonstrated to be associated with poorer disease outcome in adult
patients with CD (14). We also observed a higher rate of rectal
involvement, consistent with findings previously reported in adult
patients with CD (6,15) but contradicting others (16). We found that
inflamed skin tags may be associated with perianal fistulae detected
by pMRI but not when tags are not inflamed. Finally, pCD was
associated with higher prevalence of granulomas found in intestinal
biopsy specimens as previously reported in adults (17). The pre-
sence of granulomas has also been associated with a more aggres-
sive disease course (18).
Overall, only 4 pediatric studies compared pCD to non-pCD
patients (10,16,19,20). One study reported that pCD is associated
with anorectal inflammation and tissue granulomata (19), and in the
study by Keljo et al (16) it was associated with a greater use of
immunomodulators and biologics. None of the studies reported an
association with any other specific features suggesting a more Copyright © ESPGHAN and NA
TABLE 2. Characteristics of Patients According to Specific Perianal Pheno
Non-PA (n¼ 177) Non
Granuloma in histology, n (%) 39/167 (23%)
PGA disease activity (moderate-severe), n (%) 64 (36%)
wPCDAI, median (IQR) 20 (8–37)
MRE total inflammatory score, median (IQR) 35 (20–62)
Rectal inflammation, n (%) 67/176 (38%)
Jejunal inflammation, n (%) 18/162 (11%)
Anti-TNF exposure 70/136 (51%)
IQR¼ interquartile range; MRE¼magnetic resonance enterography; PA¼ pe
Crohn disease activity index.
Italics represents P < 0.05.
www.jpgn.orgsevere phenotype (other than younger age at presentation and
low body mass index (10)) or luminal complications.
Surprisingly, and in contrast to the increased inflammatory
activity, perianal disease was not associated with intestinal damage
as measured by radiologist global assessment of MRE, the presence
of strictures and internal fistulae, and disease progression during 18
months. In contrast to our findings, previous studies performed in
adults have shown that pCD predicted a more complicated disease
course including internal fistulizing and stenotic disease
(6,7,15,21,22). In children, 2 studies reported a higher rate of
intestinal resection in patients with pCD (10,23), although the latter
study was conducted before the introduction of biologics as an early
treatment of pCD. It is plausible to assume that we did not observe
such an association in our recent cohort because the presence of
perianal disease prompted physicians to commence anti-TNFa
agents as currently recommended (24), altering the natural history
of the disease; 71% of those with pCD and 95% of those with
fistulizing pCD were treated with anti-TNFa. The increased usage
of anti-TNFa thus likely merely reflects clinical practice rather than
a reflection of a more severe disease. Similarly, the higher pro-
portion of perianal patients treated with corticosteroids at enroll-
ment may be attributed to the known diminished efficacy of
exclusive enteral nutrition in perianal disease (24). Finally, intes-
tinal resection rate was relatively low in our study, which may have
hampered the power of prediction analyses.
Based on a comprehensive pMRI assessment we were able to
stratify patients with perianal findings into those with skin tags and/
or fissures only compared to patients with confirmed fistulizing
disease. The natural history of noninflamed skin tags is not well
documented. In adults, a single study indicated that the natural
history of skin tags or fissure is overall benign with most lesions
being stable at 10 years of follow-up (25). Our study suggests that
inflamed skin tags should be treated differently than noninflamed
tags. Of the 32 patients with noninflamed skin tags in our study only
1 had an underlying fistula demonstrated radiologically in contrast
to 3 of the 8 patients with inflamed skin tags. Even more reassuring is
the fact that the risk for developing new fistulae during 18 months was
similar between patients with noninflamed skin tags and with no
perianal findings. Supporting this notion, in a subgroup analysis, only
fistulizing perianal disease was associated with constructs of higher
inflammatory activity, whereas skin tags and fissures were not.
The mechanism by which pCD confers greater risk for a
more severe course is not well understood. The etiology of pCD
seems to involve interaction between microbiological, immuno-
logical, and genetic factors (26). It is possible that the same genetic
factors associated with severe or complicated disease such as
Nucleotide-binding oligomerization domain-containing protein 2
(NOD2) also known as caspase recruitment domain-containing
protein 15 (CARD15) and immunity-related GTPase family MSPGHAN. All rights reserved.
type (n¼234)
penetrating PA (n¼ 36) Penetrating PA (n¼ 21) Significance (P)
19/35 (54%) 16/20 (75%) 0.01
17 (47%) 17 (81%) 0.01
25 (11–40) 42 (22–60) 0.03
40 (22–60) 59 (34–72) 0.04
15/35 (43%) 17/21 (81%) 0.02
8/34 (24%) 9/20 (45%) 0.01
12/24 (50%) 15/16 (94%) 0.01
rianal; PGA¼ Physician Global Assessment; wPCDAI¼weighted pediatric
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Assa et al JPGN  Volume 65, Number 3, September 2017protein (IRGM) (27,28) also predispose to perianal disease. Only
few studies aimed at identifying genetic factors associated with
pCD, but most were limited by small sample size. An association of
pCD with a susceptibility locus on chromosome 5 has been
described (5q31) (29,30); however, other genetic association stu-
dies have confirmed neither these findings (31,32).
This is one of only a few studies assessing phenotypic and
clinic characteristics of pediatric pCD. Our results are strengthened
by the prospective nature of the study and by the comprehensive
analyses of clinical, laboratory, anthropometric, endoscopic, and
radiologic measures. Although prospective in design, the present
study has several limitations. First, despite being one of the largest
studies evaluating perianal disease in children, the number of
children with perianal involvement within the cohort is relatively
small and therefore findings may be at risk of type II error. More-
over, patients were enrolled at different time points during disease
course, confounding the longitudinal assessment. On the contrary,
the differing disease duration allowed us to explore the phenotype
of pediatric pCD during the course of disease.
In conclusion, pediatric pCD has distinct phenotypic features
and a greater inflammatory burden during the course of disease,
which is mainly driven by fistulizing disease rather than noninflamed
skin tags or fissures. In the era of standard early anti-TNFa treatment
for perianal disease, we did not observe higher rates of intestinal
damage associated with this phenotype. Therefore, our findings
support the notion that the presence of fistulizing perianal disease
reflects a more severe disease and thus warrants considering more
aggressive management approach. Isolated noninflamed skin tags
and/or fissures may not act similarly as a predictive variable and thus
may not require a radiologic evaluation or treatment escalation.
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